tiprankstipranks
Genetic Technologies (GNTLF)
OTHER OTC:GNTLF

Genetic Technologies (GNTLF) Price & Analysis

Compare
1 Followers

GNTLF Stock Chart & Stats


---

Financials

Quarterly

Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

GNTLF FAQ

What was Genetic Technologies’s price range in the past 12 months?
Genetic Technologies lowest stock price was $0.00 and its highest was $1.00 in the past 12 months.
    What is Genetic Technologies’s market cap?
    Genetic Technologies’s market cap is $5.96M.
      When is Genetic Technologies’s upcoming earnings report date?
      Genetic Technologies’s upcoming earnings report date is Aug 28, 2025 which is in 145 days.
        How were Genetic Technologies’s earnings last quarter?
        Currently, no data Available
        Is Genetic Technologies overvalued?
        According to Wall Street analysts Genetic Technologies’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Genetic Technologies pay dividends?
          Genetic Technologies does not currently pay dividends.
          What is Genetic Technologies’s EPS estimate?
          Genetic Technologies’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Genetic Technologies have?
          Currently, no data Available
          What happened to Genetic Technologies’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Genetic Technologies?
          Currently, no hedge funds are holding shares in GNTLF
          ---

          Genetic Technologies Stock Smart Score

          5
          Neutral
          1
          2
          3
          4
          5
          6
          7
          8
          9
          10

          Fundamentals

          Return on Equity
          -181.97%
          Trailing 12-Months
          Asset Growth
          -58.22%
          Trailing 12-Months

          Company Description

          Genetic Technologies

          Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.
          ---
          Similar Stocks
          Company
          Price & Change
          Follow
          CardieX Limited
          Resonance Health Ltd
          Race Oncology Ltd.
          Australian Clinical Labs Ltd
          Botanix Pharmaceuticals Limited
          Popular Stocks
          ---
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis